Interim Durability Analysis of PTX-200 Breast Cancer Study
Filed with ASX · · 3 pages · English
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- September 2018 Appendix 4C - Quarterly
- Pipeline Collaboration for Next Generation Formulations
- Change of Registry Address: Automic P/L - Sydney Office
- Improved manufacturing route for PTX-100
- Appendix 4E and 2018 Annual Report
Later from Prescient Therapeutics
- December 2018 Appendix 4C - Quarterly
- Prescient Completes Equity Raising to Raise $9.1 Million
- Capital Raising Presentation - March 2019
- Prospectus
- Despatch of Entitlement Offer Documents
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics